A Phase 1b Trial of LY2606368 in Combination With Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Apr 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cetuximab (Primary) ; Cisplatin (Primary) ; Prexasertib (Primary)
Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer; Tongue cancer
Focus Adverse reactions
Sponsors Eli Lilly and Company

26 Feb 2022 Results (n=17)evaluating immune and tumor genome signatures associated with response to radiotherapy and Chk-1 inhibition, presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium
01 Apr 2021 Results published in the Radiotherapy and Oncology Journal.
29 Feb 2020 Results presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com